The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data

References

• Mueser KT, Jeste DV, editors. Clinical handbook of schizophrenia. New York (NY): The Guilford Press; 2008.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013.
   Google Scholar
• Global Burden of Disease (GBD) 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• Murphy T, Krasa H, Lavigne G, et al. Societal costs of schizophrenia & related disorders. Alexandria (VA): Schizophrenia & Psychosis Action Alliance; 2021.
   Google Scholar
• Fitch K, Iwasaki K, Villa KF. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits. 2014;7(1):18–26.
   PubMedGoogle Scholar
• Harvey PD, Heaton RK, Carpenter WT Jr, et al. Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res. 2012;140(1–3):1–8.
   PubMed Web of Science ®Google Scholar
• Evensen S, Wisløff T, Lystad JU, et al. Prevalence, employment rate, and cost of schizophrenia in a high-income welfare society: a population-based study using comprehensive health and welfare registers. Schizophr Bull. 2016;42(2):476–483.
   PubMed Web of Science ®Google Scholar
• Khaykin E, Eaton WW, Ford DE, et al. Health insurance coverage among persons with schizophrenia in the United States. Psychiatr Serv. 2010;61(8):830–834.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 3rd ed. Washington (DC): American Psychiatric Association; 2021.
   Google Scholar
• Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942.
   PubMed Web of Science ®Google Scholar
• Semahegn A, Torpey K, Manu A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9(1):17.
   PubMed Web of Science ®Google Scholar
• Acosta FJ, Hernández JL, Pereira J, et al. Medication adherence in schizophrenia. World J Psychiatry. 2012;2(5):74–82.
   PubMedGoogle Scholar
• Munro J, Osborne S, Dearden L, et al. Hospital treatment and management in relapse of schizophrenia in the UK: associated costs. Psychiatrist. 2011;35(3):95–100.
   Google Scholar
• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218.
   PubMedGoogle Scholar
• Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(Suppl 9):5–9.
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Liu D, Ziebell S, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170(6):609–615.
   PubMed Web of Science ®Google Scholar
• van Haren NEM, Hulshoff Pol HE, Schnack HG, et al. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry. 2008;63(1):106–113.
   PubMed Web of Science ®Google Scholar
• Johnson DAW. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry. 2009;195(S52):S7–S12.
   PubMedGoogle Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Washington (DC): American Psychiatric Association; 2010.
   Google Scholar
• Keepers GA, Fochtmann LJ, Anzia JM, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry . 2020;177(9):868–872.
   PubMed Web of Science ®Google Scholar
• Girardi P, Del Casale A, Rapinesi C, et al. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Hum Psychopharmacol. 2018;33(3):e2658.
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L, et al. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry. 2013;7(3):247–254.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19(1):3–5.
   PubMed Web of Science ®Google Scholar
• Kim B, Lee SH, Yang YK, et al. Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophr Res Treatment. 2012;2012:560836.
   PubMedGoogle Scholar
• Taylor M, Ng KYB. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust N Z J Psychiatry. 2013;47(7):624–630.
   PubMed Web of Science ®Google Scholar
• Brugnoli R, Rapinesi C, Kotzalidis GD, et al. Model of management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs). Riv Psichiatr. 2016;51(2):47–59.
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treatment. 2012;2012:407171.
   PubMedGoogle Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1–24.
   PubMed Web of Science ®Google Scholar
• Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–1224.
   PubMed Web of Science ®Google Scholar
• Munday J, Greene M, Chang E, et al. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Curr Med Res Opin. 2019;35(7):1231–1239.
   PubMed Web of Science ®Google Scholar
• Abilify Maintena (aripiprazole). US prescribing information. Rockville (MD): Otsuka America Pharmaceutical, Inc.; 2020.
   Google Scholar
• Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824–836.
   PubMed Web of Science ®Google Scholar
• IBM Watson Health. IBM MarketScan research databases for life sciences researchers [internet]. Somers (NY): IBM; 2021 [cited 2022 February 14]. Available from: https://www.ibm.com/downloads/cas/OWZWJ0QO
   Google Scholar
• Clozaril (clozapine). US prescribing information. Rosemont (PA): HLS Therapeutics (USA), Inc., 2020.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Victoria KN, Cribbie RA. Using the gamma generalized linear model for modeling continuous, skewed and heteroscedastic outcomes in psychology. Curr Psychol. 2017;36:225–235.
   Web of Science ®Google Scholar
• US Bureau of Labor Statistics. Consumer price index [internet]. 2022. [cited 2022 July 15]. Available from: https://www.bls.gov/cpi/factsheets/medical-care.htm
   Google Scholar
• Broder MS, Greene M, Chang E, et al. Health care resource use, costs, and diagnosis patterns in patients with schizophrenia and bipolar disorder: real-world evidence from US claims databases. Clin Ther. 2018;40(10):1670–1682.
   PubMed Web of Science ®Google Scholar
• Karlović D, Silić A, Crnković D, et al. Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia. Hum Psychopharmacol. 2021;36(2):e2763.
   PubMed Web of Science ®Google Scholar
• Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198–219.
   PubMedGoogle Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171–1180.
   PubMed Web of Science ®Google Scholar
• Kane JM, Zhao C, Johnson BR, et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 2015;18(2):145–154.
   PubMed Web of Science ®Google Scholar
• Naber D, Baker RA, Eramo A, et al. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophr Res. 2018;192:205–210.
   PubMed Web of Science ®Google Scholar
• Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168(1–2):498–504.
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Baker RA, et al. Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: results from two multicenter, randomized, double-blind studies. Clin Schizophr Relat Psychoses. 2015;9(2):79–87.
   PubMedGoogle Scholar